We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
News

Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography
News

Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Qiagen and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Qiagen N.V. and ActiveSight have announced that they have entered into a co-marketing agreement related to protein crystallography for drug discovery.

The agreement seeks to ease access to protein crystallization reagents and crystallographic services, thereby expanding the opportunities for organizations in need of important structural biology information.

Qiagen claims that its extensive line of standardized reagents and kits now enable researchers to use a seamless solution of Qiagen products from genes all the way through to protein crystals.

Crystal analysis and structure resolution can then be performed at ActiveSight, using their advanced equipment for structural determination. ActiveSight also offers protein crystallization set-up using Qiagen reagents.

"We are very pleased to work with ActiveSight, given their reputation for excellence and leadership in the protein crystallography service field," said Jean-Pascal Viola, Qiagen's Director of Protein Crystallization.

"The bundling of Qiagen's sample preparation standards with ActiveSight's advanced service offerings creates an alternative for researchers in need of structural analysis, X-ray analysis and 3D structure resolution of their protein crystals. The endorsement of Dr. McRee validates our leadership position in the field of protein crystallization."

"We are delighted to offer Qiagen's high-quality reagents in our CrystalScan crystallization screening service," stated Duncan McRee, Ph.D., President of ActiveSight.

"Qiagen is leading the field in innovation for crystallization reagents to make structure determination more accessible and successful."

Advertisement